Pacific Biosciences Reports Q2 2026 Financial Results, Revenue Decline and Restructuring Plan

Pacific Biosciences of California, Inc. (PacBio) reported its financial results for the second quarter and first half of 2026, revealing a total revenue of $39.0 million for the three months ended June 30, 2026, a decrease of 2% from $39.8 million in the same period of 2025. For the first half of 2026, total revenue was $76.2 million, down from $76.9 million year-over-year. The company recorded a gross profit of $12.6 million for the second quarter, a decline of 14% compared to $14.7 million in the prior year, while gross profit for the first half increased significantly to $25.5 million from $13.3 million, primarily due to reduced costs of revenue.

The company’s operating loss for the second quarter was $44.6 million, slightly improved from a loss of $44.9 million in the same quarter of 2025. However, the operating loss for the first half of 2026 was $53.0 million, a substantial reduction from the $473.8 million loss reported in the first half of 2025. This improvement was attributed to a significant decrease in operating expenses, which fell to $78.4 million in the first half of 2026 from $487.1 million in the previous year, largely due to restructuring efforts and a gain on the disposal of assets.

In terms of strategic developments, PacBio has initiated a restructuring plan aimed at aligning its organizational structure with its strategic initiatives, which includes a workforce reduction of approximately 40 employees, or 8% of its workforce. This restructuring is expected to yield annualized operating expense reductions of $30 million to $40 million by the end of 2027. Additionally, the company appointed Mark Van Oene as the new President and CEO, effective August 5, 2026, succeeding Christian Henry.

Operationally, PacBio's product revenue for the first half of 2026 included $22.6 million from instrument sales, $41.9 million from consumables, and $11.7 million from service and other revenue. The company noted a decrease in instrument sales, particularly for its Vega systems, which sold 53 units compared to 66 units in the same period of 2025. However, sales of Revio systems increased, with 35 units sold compared to 27 in the prior year. The company anticipates continued growth in consumables revenue driven by the expansion of the Revio and Vega installed bases and the recent launch of SPRQ-Nx.

Looking ahead, PacBio remains optimistic about its revenue growth potential, particularly in the clinical sequencing market, despite facing challenges such as funding constraints and longer sales cycles. The company expects revenues to improve in the second half of 2026, supported by ongoing clinical adoption and the growth of consumable sales. However, it also acknowledges potential risks from macroeconomic factors, including inflation and supply chain constraints, which could impact future performance.